NEW YORK (GenomeWeb) – Swiss diagnostics firm ProteoMedix said today that it has closed a CHF 5 million ($5.2 million) equity financing round.

The company said it plans to use the funds to obtain CE-IVD marking for its lead product, a proteomic test for diagnosing prostate cancer, as well as to collect more clinical data. It also plans to develop an additional test for prostate cancer prognosis.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.